Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer

Clinical Genitourinary Cancer

Volumn 6, Issue SUPPLEMENT 1, 2008, Pages

  Chung, Elizabeth K ^a   Stadler, Walter M ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Cardiovascular toxicity; Plateletderived growth factor; Tyrosine kinase inhibitors; Von Hippel Lindau

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ALPHA2A INTERFERON; ATROPINE PLUS DIPHENOXYLATE; AXITINIB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CEDIRANIB; DILTIAZEM; DIPHENHYDRAMINE; DIURETIC AGENT; HYDROCORTISONE; IMATINIB; INTERFERON; INTERLEUKIN 2; LENALIDOMIDE; LEVOTHYROXINE; LOPERAMIDE; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; VASCULOTROPIN; VERAPAMIL; VOLOCIXIMAB;

ANASTOMOSIS LEAKAGE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DESQUAMATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; EPISTAXIS; FATIGUE; FISTULA; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INTESTINE PERFORATION; KIDNEY CANCER; KIDNEY FAILURE; KIDNEY METASTASIS; MULTIPLE CYCLE TREATMENT; PROTEINURIA; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; STOMATITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT;

EID: 70349308400     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2008.s.004     Document Type: Article

References (81)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Lam JS, Belldegrun AS, Figlin RA. Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther 2004;4:1081-96.
3. Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843-52.
4. (Pubitemid 29368255) Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
5. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
6. Lane BR, Kattan M. W. Predicting outcomes in renal cell carcinoma. Curr Opin Urol 2005;15:289-97.
7. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90.
8. (Pubitemid 41079774) Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63.
9. Stadler WM. Cytotoxic chemotherapy for metastatic renal cell carcinoma. Urologe A 2004;43(suppl 3):145-6.
10. Motzer RJ, Russo P, Nanus DM, et al. Renal cell carcinoma. Curr Probl Cancer 1997;21:185-232.
11. (Pubitemid 30060482) Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17.
12. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 2007;356:185-7.
13. (Pubitemid 46631340) Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol 2006;24:5593-600.
14. (Pubitemid 36109749) Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
15. (Pubitemid 46630489) Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
16. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
17. (Pubitemid 46089672) Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
18. Cella D, Li JZ, Cappelleri JC, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 2008;26:3763-9.
19. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN) -alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26(15 suppl):256s (Abstract 5024).
20. (Pubitemid 39331023) Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
21. (Pubitemid 46630627) Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
22. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma [published erratum appears in: N Engl J Med 2007;357:203].
23. N Engl J Med 2007;356:125-34.
24. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 2007;25(18 suppl):240s (Abstract 5023).
25. (Pubitemid 46884139) Bukowski R, Cella D, Gondek K, et al. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007;30:220-7.
26. Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007;25(18 suppl):241s (Abstract 5025).
27. Fabian MA, Biggs WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36.
28. Amato RJ, Harris P, Dalton M, et al. A phase II trial of intra-patient dose-escalated sorafenib in patients with metastatic renal cell cancer (MRCC). J Clin Oncol 2007;25(18 suppl):241s (Abstract 5026).
29. (Pubitemid 47629888) Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8:975-84.
30. Dutcher JP, Wilding G, Hudes GR, et al. Sequential axitinib (AG-013736) therapy of patients with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol 2008;26(15 suppl):281s (Abstract 5127).
31. Clinicaltrials.gov [Web site]. Axitinib (Ag 013736) as second line therapy for metastatic renal cell cancer. Available at: http://clinicaltrials. gov/ct2/show/NCT00678392?term=r enal+cancer+sorafenib+and+axitinib&rank=1. Accessed: December 5, 2008.
32. (Pubitemid 40775678) Wedge SR, Kendrew J, Hennequin L F, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-400.
33. Heckman CA, Holopainen T, Wirzenius M, et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 2008;68:4754-62.
34. (Pubitemid 351786743) Nikolinakos P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J Thorac Oncol 2008; 3:S131-4.
35. Sridhar SS, Mackenzie MJ, Hotte SJ, et al. Activity of cediranib (AZD2171) in patients with previously untreated metastatic renal cell cancer: a phase II trial of the PMH Consortium. J Clin Oncol 2008;26(15 suppl):261s (Abstract 5047).
36. Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC) : interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2007;25(18 suppl):242s (Abstract 5031).
37. Clinicaltrials.gov [Web site]. Pazopanib versus sunitinib in the treatment of locally advanced/metastatic renal cell carcinoma. Available at: http://clinicaltrials.gov/ct2/show/NCT00720941?term= renal+cancer+and+pazopanib&rank=5. Accessed: December 5, 2008.
38. (Pubitemid 36910021) Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
39. (Pubitemid 350296300) Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
40. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-8.
41. Rini BI, Rathmell WK. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res 2007; 13:741s-6s.
42. Dupont J, Rothenberg ML, Spriggs DR, et al. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 2005;23(16 suppl):199s (Abstract 3029).
43. Clinicaltrials.gov [Web site]. VEGF Trap in treating patients with metastatic or unresectable kidney cancer. Available at: http://clinicaltrials. gov/ct2/show/NCT00 357760?term=E4805&rank=1. Accessed: December 5, 2008.
44. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-30.
45. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81-3.
46. Sutent (sunitinib) [prescribing information]: New York, NY: Pfizer Inc.; 2008.
47. Nexavar (sorafenib) [prescribing information]: Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc.; 2008.
48. Avastin (bevacizumab) [label]: South San Francisco, CA: Genentech, Inc.; 2008.
49. Dutcher J P, Rixe O, Motzer RJ, et al. Levothyroxine treatment of hypothyroidism and axitinib (AG-013736) efficacy in patients (pts) with metastatic renal cell carcinoma (MRCC). Ann Oncol 2008; 19 (suppl 8):viii194 (Abstract 600P).
50. (Pubitemid 350186998) Garfield D, Hercbergs A, Davis P. Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nat Clin Pract Oncol 2007; 4:674.
51. Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008;9:117-23.
52. Maitland ML, Moshier K, Imperial J, et al. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. J Clin Oncol 2006;24(18 suppl):87s (Abstract 2035).
53. Medioni J, Cojocarasu O, Banu E, et al. Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Targ Oncol 2007;2:193-5.
54. (Pubitemid 43313687) Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980-2.
55. (Pubitemid 350296582) Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008;53:376-81.
56. Telli ML, Witteles RM, Fisher GA, et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008;19:1613-8.
57. Chu D, Lacouture ME, Fillos T, et al. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008;47:176-86.
58. Lacouture ME, Reilly LM, Gerami P, et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19:1955-61.
59. Wood LS, Manchen B. Sorafenib: a promising new targeted therapy for renal cell carcinoma. Clin J Oncol Nurs 2007;11:649-56.
60. François H, Coppo P, Hayman JP, et al. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis 2008;51:298-301.
61. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-36.
62. (Pubitemid 44869016) Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127-39.
63. (Pubitemid 41254420) Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-80.
64. Thibault F, Billemont B, Rixe O. Perioperative use and surgical complications of sunitinib in metastatic renal cell carcinoma. Eur Urol Suppl 2008; 7:306.
65. Eng FC, Easson AM, Szentgyorgyi E, et al. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. Eur J Surg Oncol 2007; e-pub ahead of print.
66. (Pubitemid 351325682) Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008;19:577-82.
67. Flaig TW, Kim FJ, La Rosa FG, et al. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs 2008; e-pub ahead of print.
68. Sosman JA, Flaherty KT, Atkins MB, et al. Update results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008;26(15 suppl):252s (Abstract 5011).
69. Feldman DR, Ginsberg MS, Baum M, et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26(15 suppl):274s (Abstract 5100).
70. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first-or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25:3288-95.
71. Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007;25:3296-301.
72. Patnaik A, Ricart A, Cooper J, et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J Clin Oncol 2007;25(18 suppl):141s (Abstract 3512).
73. Merchan JR, Liu G, Fitch T, et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol 2007;25(18 suppl):243s (Abstract 5034).
74. Clinicaltrials.gov [Web site]. Bevacizumab, sorafenib, and temsirolimus in treating patients with metastatic kidney cancer. 2008. Available at: http://clinicaltrials.gov/ct2/show/NCT00378703?term= bevacizumab+sorafenib+temsirolimus&rank=1. Accessed: December 5, 2008.
75. Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol 2007;25(18 suppl):261s (Abstract 5106).
76. Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. J Clin Oncol 2007;25(18 suppl):244s (Abstract 5038).
77. (Pubitemid 350216728) Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81-6.
78. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8.
79. Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients with metastatic clear cell renal cell carcinoma refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008;26(15 suppl):280s (Abstract 5123).
80. (Pubitemid 34441667) Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20:2376-81.
81. Stadler WM, Figlin RA, Ernstoff MS, et al, on behalf of the ARCCS investigators. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: safety and efficacy in patients with non-clear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol 2007;25(18 suppl):243s (Abstract 5036).